NCT07897734
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
StatusNot Yet Recruiting
PhasePhase 1/2
SponsorTango Therapeutics, Inc.
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Phase 1 Maximum Tolerated Dose
Timeframe: 21 days
Phase 2 Combination Anti-neoplastic Activity
Timeframe: 12 weeks
Secondary (3)
Phase 1 and 2 Combination Anti-neoplastic Activity
Phase 1 and 2 PK Profile of vopimetostat and ERAS-0015 in Combination
Phase 1 and 2 Adverse Event Profile
Arms and interventions
Dose Escalation PDACExperimental
Escalating doses of vopimetostat in combination with ERAS-0015
Dose expansion 1L PDACExperimental
Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015
Dose Expansion 2L PDACExperimental
Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015
Dose Expansion 2L or 3L NSCLCExperimental
Expansion arm at the RD(s) of vopimetostat in combination with ERAS-0015
Drugs: vopimetostat, ERAS-0015